GlassScriptPhysician profile
Piotr Kulikowski
NPI 1053388678
$28,794.54
in general payments reported to CMS, 2019-2025
61 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,546 · 2020: $1,524 · 2021: $1,775 · 2022: $1,179 · 2023: $1,871 · 2024: $3,215 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $9,776 · Education: $81.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,913.28 |
| Food and Beverage | $9,775.67 |
| Education | $81.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $12,937.42 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,592.92 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,546.69 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $854.37 | 2019-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $768.74 | 2024-2025 | Auvelity |
| Amgen INC. | $698.63 | 2019-2025 | Repatha, Repatha, Otezla |
| Astellas Pharma US INC | $696.22 | 2019-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $649.40 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $632.28 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $586.91 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $562.04 | 2021-2025 | |
| Novo Nordisk INC | $528.88 | 2019-2025 | Wegovy |
| Vanda Pharmaceuticals INC. | $491.17 | 2024-2025 | Fanapt |
| Pfizer INC. | $426.97 | 2019-2025 | |
| Abbvie INC. | $341.70 | 2020-2024 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Piotr Kulikowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.